OGI.V - OrganiGram Holdings Inc.

TSXV - TSXV Delayed Price. Currency in CAD
8.24
-0.15 (-1.79%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close8.39
Open8.39
Bid8.24 x 0
Ask8.27 x 0
Day's Range8.20 - 8.52
52 Week Range4.11 - 11.30
Volume386,227
Avg. Volume1,188,632
Market Cap1.287B
Beta (3Y Monthly)4.12
PE Ratio (TTM)37.12
EPS (TTM)0.22
Earnings DateJul 27, 2017 - Jul 28, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.98
  • Weekly Cannabis Stock News: Curaleaf Makes a Power Play
    Motley Foolyesterday

    Weekly Cannabis Stock News: Curaleaf Makes a Power Play

    Curaleaf is buying expansion with its $875 acquisition of Grassroots. Meanwhile, OrganiGram reported Q3 results, and Aurora Cannabis had a good news/bad news week.

  • Cannabis Stocks Are Crashing: 3 Pot Stocks on Sale
    Motley Fool2 days ago

    Cannabis Stocks Are Crashing: 3 Pot Stocks on Sale

    A recent tumble in marijuana stocks may offer a great buy opportunity.

  • 3 Cannabis Stocks Worth Considering for Your Portfolio
    Motley Fool3 days ago

    3 Cannabis Stocks Worth Considering for Your Portfolio

    MediPharm Labs, Canopy Growth, and OrganiGram get some love from three of our contributors who cover the marijuana space.

  • Thomson Reuters StreetEvents4 days ago

    Edited Transcript of OGI.V earnings conference call or presentation 15-Jul-19 12:00pm GMT

    Q3 2019 OrganiGram Holdings Inc Earnings Call

  • Cultivation and Product Expansion Take Focus as OrganiGram Reports a Modest Third-Quarter Loss
    Motley Fool5 days ago

    Cultivation and Product Expansion Take Focus as OrganiGram Reports a Modest Third-Quarter Loss

    OrganiGram remains on track to complete its Moncton campus by year's end, and is eagerly awaiting the launch of derivative cannabis products in December.

  • Organigram a Canadian Pot Rarity After Four Profitable Quarters
    Bloomberg5 days ago

    Organigram a Canadian Pot Rarity After Four Profitable Quarters

    (Bloomberg) -- With four quarters of profitability under its belt, Organigram Holdings Inc. is an anomaly in the Canadian cannabis market.Organigram has higher margins than most of its peers and one of the lowest costs per gram in the industry even though it grows indoors, generally considered the most expensive method of production. Chief Executive Officer Greg Engel attributes this to its ability to get higher yields from its pot plants than companies that grow in greenhouses, as well as its automated packaging lines.“We built a facility and designed a facility that was very focused on high-quality product because we felt there was a market opportunity that was sustainable,” Engel said in an interview at Bloomberg’s Toronto office.Organigram’s streak of profitability comes as the industry undergoes a period of significant upheaval. CannTrust Holdings Inc., previously considered one of the more reputable pot companies, plunged 48% last week after Canadian regulators said it grew cannabis in unlicensed areas of its greenhouse, forcing it to halt all sales and shipments of its products.That came less than a week after Canopy Growth Corp. fired co-CEO Bruce Linton amid shrinking margins and a C$323 million net loss in its most recent quarter.Lower ValuationMoncton, New Brunswick-based Organigram, meanwhile, reported its fourth consecutive quarter on Monday of positive adjusted earnings before interest, taxes, depreciation and amortization, or Ebitda. Revenue of C$25 million ($19 million) missed estimates and gross margin fell to 50% from 60% in the previous quarter, but Eight Capital analyst Graeme Kreindler said he views this as an “isolated event” related to a temporary change in cultivation protocols and the timing of shipments to provinces.Organigram said it cost 95 cents to produce a gram of dried flower in its most recent quarter. That was up from 65 cents in the previous quarter but still compares favorably with C$1.42 at Aurora Cannabis Inc. and $1.48 at Tilray Inc.No other large Canadian pot producer has managed to post such a long string of positive Ebitda. However, although it’s one of the best-performing pure-play pot stocks this year, up 64%, its valuation as measured by its price-to-sales ratio is well below those of its largest competitors.Engel is unperturbed. “At the end of the day, the worst thing that can happen to a company is you’ve got an artificial stock price that you can’t sustain,” Engel said.Competitors also spend a lot on stock promotion, he said. This “may in the short term be helping their stock price, but I’m not sure that’s sustainable without ongoing spending,” he said.The problems at CannTrust and Canopy signal a shakeout in an industry that’s still maturing nine months after Canada legalized recreational pot. Organigram is lucky because it had its wake-up call early, said Engel.The company had to recall several lots of its medical pot in late 2016 and early 2017 after it was found to contain an unapproved pesticide. Engel, who was CEO of Tilray Inc. at the time, was hired after the recall to “make a major cultural shift,” he said.“As a result of that recall, we had monthly ongoing inspections by regulators, and historically the industry was always complaining or defensive about the inspections,” Engel said. “My approach was to embrace them. At the end of the day it’s a partnership, not an adversarial relationship.”In the interview, Engel shared his views of the nascent industry:Beverages and EdiblesOrganigram isn’t being coy about its desire for a partner that can help it develop cannabis-infused beverages, similar to Constellation Brands Inc.’s investment in Canopy, Tilray’s partnership with Anheuser-Busch InBev SA or Hexo Corp.’s joint venture with Molson Coors Brewing Co.Organigram has developed a rapid-onset technology that will allow its drinks to take effect within 10 to 15 minutes, similar to alcohol, and has also created a flavorless cannabis powder that can be added to any beverage.“We wanted to go to these negotiations offering as much as possible,” Engel said. Organigram is seeking a partner from the alcohol industry that can help it develop beverages infused with THC, the cannabis compound that gets you high. It’s also seeking a consumer packaged goods partner for drinks infused with CBD, a non-intoxicating substance that’s thought to have health and wellness properties.BiosyntheticsEngel hopes Organigram’s investment in Montreal-based Hyasynth Biologicals Inc. will also help it lure a partner. Hyasynth is developing large-scale biosynthetic production of cannabinoids, or the active compounds found in cannabis. This method, which uses yeast to produce the compounds in a lab, is cheaper than extracting them from plants and will help lower production costs for products like beverages, edibles and vape pens, said Engel.U.S. Market“We’re very actively looking at the CBD market in the U.S.,” where the substance is legal at the federal level as long as it’s derived from hemp with very low THC content, Engel said. Organigram doesn’t plan to grow its own hemp but is looking at a range of possibilities, including investments in existing brands, products and companies.Corporate GovernanceOrganigram has a fully independent board of directors, a rarity in the cannabis sector. The CEO sees good corporate governance as essential to a well-run pot company.“This is an industry that’s still very much moving from founders and executives being chairmen or multiple insiders on boards, and I think some of the challenges we’ve seen in the industry have been because of a lack of governance,” he said. “You have to have independent governance that has oversight and holds management accountable.”To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, ;David Scanlan at dscanlan@bloomberg.net, Jacqueline ThorpeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • After Hours: CBS and Viacom Apparently Set a Date, OrganiGram Nixes Experiment
    Motley Fool5 days ago

    After Hours: CBS and Viacom Apparently Set a Date, OrganiGram Nixes Experiment

    The looming merger in big entertainment seemingly has a deadline, and a big reason for a marijuana stock's quarterly loss is revealed.

  • Marijuana Stocks Rise Despite Organigram Loss; Aurora Cannabis Lands Cultivation Licenses
    Investor's Business Daily6 days ago

    Marijuana Stocks Rise Despite Organigram Loss; Aurora Cannabis Lands Cultivation Licenses

    Organigram earnings missed Q3 views. Aurora Cannabis got two new cultivation licenses. Organigram, Aurora and other marijuana stocks rose.

  • Barrons.com6 days ago

    OrganiGram Stock Rises Even as Cannabis Sales Fall

    The shortfall could reinforce worries about recreational marijuana demand in the year after Canada legalized such sales in October 2018.

  • Benzinga6 days ago

    Organigram Falls Despite Q3 Revenue Growth

    Cannabis company OrganiGram Holdings Inc. (NASDAQ: OGI) released its third-quarter financial report Monday morning. Organigram reported a quarterly net loss from continuing operations of CA$10.2 million or 7 cents per share on a diluted basis.. Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!

  • 10 Pure-Play Pot Stocks Forecast to Make Money in 2019
    Motley Fool6 days ago

    10 Pure-Play Pot Stocks Forecast to Make Money in 2019

    Despite supply and tax problems, some cannabis stocks are expected to make money this year.

  • Business Wire6 days ago

    Organigram Reports Third Quarter Fiscal 2019 Results

    MONCTON, New Brunswick-- -- Q3 and year to date 2019 1 net revenue of $24.8 million and $64.1 million, respectively, and Q3 net loss and net income from continuing operations of $10.2 million and $12.9 million, respectively Q3 and year to date gross margin, which includes the impact of fair value adjustments was and $59.5 million, respectively. Excluding the impact of non-cash fair value adjustments, ...

  • The 3 Most Profitable Marijuana Stocks You Can Buy Right Now
    Motley Fool7 days ago

    The 3 Most Profitable Marijuana Stocks You Can Buy Right Now

    Nearly all publicly traded cannabis companies are losing money at the moment, but not these three.

  • This Major Marijuana Grower Reiterates Its Desire to Find a Beverage Partner
    Motley Fool10 days ago

    This Major Marijuana Grower Reiterates Its Desire to Find a Beverage Partner

    Three brand-name beverage companies could be the perfect partner for this Atlantic-based pot stock.

  • Benzinga11 days ago

    Organigram, Lift & Co. Collaborate On Educational Program

    Canada’s first branded cannabis oriented educational program is on its way, thanks to a newly announced collaboration between Organigram Holdings Inc. (NASDAQ: OGI) (TSX:OGI) and Lift & Co. Corp (TSXV:LIFT) (OTCQB: LFCOF). Organigram is concentrated on the production of high-quality, indoor-grown cannabis both for patients and adult recreational consumers. Among the company’s famous brands are Trailer Park Buds, The Edison Cannabis Company, and Ankr Organics.

  • Business Wire11 days ago

    Organigram and Lift & Co. Enhance Education of Cannabis Frontline Staff via Brand-Specific Training Program

    Organigram Holdings Inc. (OGI) (TSX VENTURE: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce a collaboration with Lift & Co. Corp ("Lift & Co.") (LIFT.V) (LFCOF) to support the launch of Canada’s first branded cannabis educational program via Lift & Co.’s CannSell retail training program.

  • Barrons.com12 days ago

    BMO Analyst Trims Outlook for Two Marijuana Stocks

    Faltering marijuana deliveries and regulatory troubles lead Tamy Chen to reconsider OrganiGram and CannTrust.

  • 3 Popular Pot Stocks That Had a Terrible June
    Motley Fool12 days ago

    3 Popular Pot Stocks That Had a Terrible June

    Having a brand name didn't save these marijuana stocks from a double-digit percentage decline.

  • Why Marijuana Stock OrganiGram Popped 8% Today -- and Gained 80% in the First Half of 2019
    Motley Fool12 days ago

    Why Marijuana Stock OrganiGram Popped 8% Today -- and Gained 80% in the First Half of 2019

    This small-cap cannabis stock is outperforming Canopy, Aurora, Cronos, and nearly all marijuana stocks so far this year.

  • Benzinga13 days ago

    OrganiGram Announces Proprietary Technology For Cannabis-Infused Edibles

    OrganiGram's proprietary technology uses nano-emulsion that creates micro-droplets that are very small and uniform. The technology is stable to temperature variations, as well as other factors, such as mechanical disturbance, salinity, pH and sweeteners. Organigram's scientists also figured out how to use the emulsification system to transform the formulation into a dissolvable powder.

  • Why OrganiGram Holdings, Shopify, and Weight Watchers International Jumped Today
    Motley Fool13 days ago

    Why OrganiGram Holdings, Shopify, and Weight Watchers International Jumped Today

    Find out how these stocks defied a down market.

  • Business Wire13 days ago

    Organigram Announces Expanded Development of Rapid-Onset Nano-Emulsification Technology for Cannabis Beverages

    In anticipation of the legalization of adult use recreational cannabis edibles in Canada, as well as consumer demand for cannabis-infused beverages, Organigram Holdings Inc. (TSX VENTURE: OGI) (OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, has developed a proprietary nano-emulsification technology that will allow for the production of both liquid and powdered cannabinoid products.

  • The 2 Pot Stocks Former Canopy Growth Co-CEO Bruce Linton Thinks You Should Buy
    Motley Fool13 days ago

    The 2 Pot Stocks Former Canopy Growth Co-CEO Bruce Linton Thinks You Should Buy

    No longer constrained by role as co-CEO, Linton handpicked these two marijuana stocks as possible investments.

  • The Tech Breakthrough Set To Reshape Cannabis Markets
    Oilprice.com14 days ago

    The Tech Breakthrough Set To Reshape Cannabis Markets

    The global legal cannabis market is growing at breakneck speed, but there’s one thing that keeps it from growing into a trillion dollar market – legitimacy

  • Looking for Pot Stock Tips? Canopy Growth's Ex-CEO Just Gave 3 of Them
    Motley Fool15 days ago

    Looking for Pot Stock Tips? Canopy Growth's Ex-CEO Just Gave 3 of Them

    Bruce Linton is out as Canopy Growth's CEO. But he has some ideas on which cannabis stocks investors should consider buying.